Wall Street brokerages predict that Merus (NASDAQ:MRUS) will report $7.52 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Merus' earnings. The highest sales estimate is $8.50 million and the lowest is $7.00 million. Merus posted sales of $9.02 million during the same quarter last year, which suggests a negative year-over-year growth rate of 16.6%. The firm is scheduled to issue its next earnings report on Tuesday, November 10th.
According to Zacks, analysts expect that Merus will report full-year sales of $27.23 million for the current year, with estimates ranging from $26.30 million to $29.60 million. For the next year, analysts expect that the company will post sales of $29.80 million, with estimates ranging from $27.68 million to $33.33 million. Zacks Investment Research's sales averages are an average based on a survey of sell-side analysts that cover Merus.
Merus (NASDAQ:MRUS) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.59). Merus had a negative return on equity of 66.84% and a negative net margin of 243.85%. The business had revenue of $6.67 million for the quarter, compared to analyst estimates of $6.79 million.
A number of brokerages recently issued reports on MRUS. HC Wainwright reissued a "buy" rating and issued a $23.00 target price on shares of Merus in a research report on Friday, August 7th. Zacks Investment Research raised Merus from a "hold" rating to a "strong-buy" rating and set a $14.00 price target on the stock in a research report on Wednesday, October 7th. Finally, BidaskClub lowered Merus from a "sell" rating to a "strong sell" rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Merus has a consensus rating of "Buy" and an average price target of $19.00.
In other Merus news, major shareholder Bvf Partners L. P/Il bought 189,651 shares of Merus stock in a transaction dated Thursday, September 10th. The stock was bought at an average cost of $11.10 per share, for a total transaction of $2,105,126.10. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Bvf Partners L. P/Il bought 201,906 shares of Merus stock in a transaction dated Thursday, September 3rd. The shares were acquired at an average price of $11.17 per share, with a total value of $2,255,290.02. The disclosure for this purchase can be found here. Insiders have bought a total of 538,311 shares of company stock valued at $6,084,776 over the last quarter. 7.40% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE bought a new stake in Merus in the 2nd quarter valued at $32,000. PDT Partners LLC bought a new stake in shares of Merus during the 2nd quarter valued at $187,000. Bank of New York Mellon Corp bought a new stake in shares of Merus during the 2nd quarter valued at $275,000. Sanders Morris Harris LLC bought a new stake in shares of Merus during the 3rd quarter valued at $333,000. Finally, Two Sigma Advisers LP lifted its position in shares of Merus by 9.9% during the 1st quarter. Two Sigma Advisers LP now owns 43,100 shares of the biotechnology company's stock valued at $522,000 after acquiring an additional 3,900 shares during the period. Institutional investors and hedge funds own 64.02% of the company's stock.
Shares of Merus stock opened at $13.05 on Friday. The business's 50 day simple moving average is $11.97 and its 200 day simple moving average is $13.56. Merus has a 52-week low of $10.18 and a 52-week high of $20.64. The firm has a market cap of $379.00 million, a PE ratio of -4.87 and a beta of 0.54.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers.
Featured Article: What is an investor looking for in an SEC filing?
Get a free copy of the Zacks research report on Merus (MRUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Stocks to Own For the Next Decade
According to Blackrock (NYSE:BLK) analysts, investors who are looking for growth as the economy begins to recover need to be in stocks. In fact, many investors are breathing a sigh of relief for not panicking when the market sold off in February and March.
But while a Black Swan event like the Covid-19 pandemic can teach investors short-term lessons, the trick to buy-and-hold investing is identifying companies that give you the confidence to invest for not just 10 weeks, but 10 years.
For many investors this means identifying key trends. Prior to the pandemic, trends were emerging. Those trends, such as e-commerce, financial technology, digital healthcare, are quickly becoming part of our “new normal.” Think about it. Cash is now literally “dirty money”. E-commerce is not just convenient, it’s essential. And we’ve figured out that the patient-doctor relationship can take place via videochat.
And all of this feeds into other trends, which includes the idea that our smartphones are only going to become more powerful, and more important. But the next 10 years are not destined to be the decade of stealth small-caps. Many of the companies that are well positioned for the next decade will be familiar to most investors.
Here are 7 companies that are going to become increasingly relevant over the next decade. When you buy them now, you’ll be thanking yourself when the calendar turns to 2030.
View the "7 Stocks to Own For the Next Decade".